We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Plasma Calprotectin and New-onset Type 2 Diabetes in the General Population: A Prospective Cohort Study.
- Authors
Bourgonje, Arno R; Bourgonje, Martin F; Sokooti, Sara; Gemert, Sacha la Bastide-van; Nilsen, Tom; Hidden, Clara; Gansevoort, Ron T; Mulder, Douwe J; Hillebrands, Jan-Luuk; Bakker, Stephan J L; Beek, André P van; Dullaart, Robin P F; Goor, Harry van; Abdulle, Amaal E
- Abstract
Context Systemic inflammation plays a pivotal role in the development of type 2 diabetes (T2D). Objective We hypothesized that circulating levels of calprotectin, a myeloid cell-derived biomarker of inflammation, is associated with the development of new-onset T2D in the general population. Methods A total of 4815 initially nondiabetic participants of the Prevention of Renal and Vascular End-stage Disease (PREVEND), a prospective population-based cohort study, were assessed for plasma levels of calprotectin at baseline. Circulating levels of calprotectin were investigated for potential associations with the risk of new-onset T2D, defined as a fasting plasma glucose level of 7.0 mmol/L or greater, a random plasma glucose level of 11.1 mmol/L or greater, a self-reported physician-based diagnosis of T2D, the use of glucose-lowering drugs, or any combinations thereof. Results Median plasma calprotectin levels were 0.49 (0.35-0.69) mg/L. Plasma calprotectin levels were significantly associated with the risk of new-onset T2D (hazard ratio [HR] per doubling 1.42 [95% CI, 1.22-1.66]; P <.001). The association remained independent of adjustment for age and sex (HR 1.34 [95% CI, 1.14-1.57]; P <.001), but not after further adjustment for potentially confounding factors (HR 1.11 [95% CI, 0.90-1.37]; P =.326), with adjustment for hyperlipidemia and high-sensitivity C-reactive protein explaining the loss of significance. Stratified analyses showed significant effect modification by hypertension, history of cardiovascular disease (CVD), the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) (P interaction ≤.001 for each), and the use of lipid-lowering drugs (P interaction ≤.05), with higher HRs in individuals without hypertension, without history of CVD, with below-median HOMA-IR, and in those not using lipid-lowering drugs. Conclusion Elevated plasma levels of calprotectin are associated with a higher risk of developing T2D in the general population and may represent a moveable inflammatory biomarker. This association, however, does not represent a direct effect, and seems dependent on hyperlipidemia and systemic inflammation.
- Subjects
TYPE 2 diabetes; BLOOD sugar; CHRONIC kidney failure; CALPROTECTIN; INSULIN resistance
- Publication
Journal of Clinical Endocrinology & Metabolism, 2025, Vol 110, Issue 1, pe150
- ISSN
0021-972X
- Publication type
Academic Journal
- DOI
10.1210/clinem/dgae130